CTSO - Cytosorbents Corporation
| Previous Close | 8.23 |
| Open | 8.29 |
| Bid | 8.06 x 800 |
| Ask | 8.50 x 900 |
| Day's Range | 8.17 - 8.49 |
| 52 Week Range | 6.67 - 14.95 |
| Volume | 114,134 |
| Avg. Volume | 179,332 |
| Market Cap | 266.825M |
| Beta (3Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.50 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.30 |
- PR Newswire•18 days ago
CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference
MONMOUTH JUNCTION, N.J., Feb. 5, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the 21st Annual BIO CEO & Investor Conference next week in New York City.
- Zacks Small Cap Research•19 days ago
CTSO: DSMB Recommends Continuance of REMOVE Study: Has several important implications
CytoSorbents (CTSO) announced this morning that the Data Safety Monitoring Board overseeing REMOVE, the company’s Germany-based study funded by the German government and which is evaluating safety and efficacy of CytoSorb in patients with infective endocarditis undergoing valve replacement surgery, recommended that the study continue. As a reminder, REMOVE is evaluating safety and efficacy of CytoSorb in patients with infective endocarditis undergoing valve replacement surgery.
- PR Newswire•19 days ago
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
MONMOUTH JUNCTION, N.J. , Feb. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...
- ACCESSWIRE•22 days ago
LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
- GlobeNewswire•last month
Detailed Research: Economic Perspectives on Shell Midstream Partners, Interface, National Western Life Group, TPG Specialty Lending, Francesca's, and Cytosorbents — What Drives Growth in Today's Competitive Landscape
NEW YORK, Jan. 23, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•last month
CytoSorbents Announces Expansion of CytoSorb® Partnership with Fresenius Medical Care
MONMOUTH JUNCTION, N.J., Jan. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced today that it has expanded its partnership with Fresenius Medical Care to Korea and Mexico. Under the terms of the agreement, Fresenius Medical Care has the exclusive rights to distribute CytoSorb for acute care and other hospital applications in Korea and Mexico.
- Simply Wall St.•last month
Is Cytosorbents Corporation’s (NASDAQ:CTSO) CEO Pay Fair?
Phillip Chan became the CEO of Cytosorbents Corporation (NASDAQ:CTSO) in 2009. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider the Read More...
- Zacks Small Cap Research•2 months ago
CTSO: Q4 / FY 2018: Record Product Sales in Q4, Jumps 51% in 2018
CytoSorbents (CTSO) preannounced expected product and total revenue for Q4 and fiscal 2018. For the quarter, product sales are anticipated to come in at $5.4M, implying growth of 26% yoy and up about 6% from Q3. For the full year, product sales are up 51% (from $13.4M in 2017) to $20.2M.
- PR Newswire•2 months ago
CytoSorbents Issues Stockholder Letter with Preliminary 2018 Financial Results
MONMOUTH JUNCTION, N.J., Jan. 7, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, and pre-announces preliminary unaudited fourth quarter 2018 and full-year 2018 results ahead of filing its Form 10-K.
- PR Newswire•2 months ago
CytoSorbents To Highlight Progress at Biotech Showcase 2019
MONMOUTH JUNCTION, N.J. , Jan. 4, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb ® blood filter to treat deadly inflammation ...
- PR Newswire•2 months ago
CytoSorbents To Receive $619,546 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
MONMOUTH JUNCTION, N.J. , Dec. 21, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly ...
- Simply Wall St.•2 months ago
Is Cytosorbents Corporation’s (NASDAQ:CTSO) Balance Sheet Strong Enough To Weather A Storm?
Investors are always looking for growth in small-cap stocks like Cytosorbents Corporation (NASDAQ:CTSO), with a market cap of US$295m. However, an important fact which most ignore is: how financially healthy Read More...
- PR Newswire•3 months ago
CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference
MONMOUTH JUNCTION, N.J. , Nov. 26, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to ...
- PR Newswire•3 months ago
CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte's 2018 Technology Fast 500™
MONMOUTH JUNCTION, N.J., Nov. 19, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company was once again recognized as one of the fastest growing companies in North America on Deloitte's 2018 Technology Fast 500™, a ranking of the top 500 technology, media, telecommunications, healthcare and life sciences, and energy tech companies in terms of revenue growth on the continent. The Company's revenues grew by 267% in the three-year period from 2014 to 2017.
- PR Newswire•3 months ago
CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week
MONMOUTH JUNCTION, N.J. , Nov. 12, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to ...
- Zacks Small Cap Research•3 months ago
CTSO: Q3: Another Solid Quarter. Financials In-Line, REFRESH II Enrollment Accelerating
By Brian Marckx, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT Q3 2018 Update : Another Solid Quarter. Financials In-Line, REFRESH II Enrollment Accelerating… CytoSorbents (NASDAQ:CTSO) reported financial ...
- Associated Press•4 months ago
CytoSorbents: 3Q Earnings Snapshot
On a per-share basis, the Monmouth Junction, New Jersey-based company said it had a loss of 10 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- PR Newswire•4 months ago
CytoSorbents Reports Third Quarter 2018 Financial Results
Achieved record $19.1M in trailing 12-month product sales, up 63% from a year ago MONMOUTH JUNCTION, N.J. , Nov. 6, 2018 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) a critical care immunotherapy ...
- Simply Wall St.•4 months ago
Cytosorbents Corporation (NASDAQ:CTSO) Is Trading At A 28.36% Discount
How far off is Cytosorbents Corporation (NASDAQ:CTSO) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairly Read More...
- PR Newswire•4 months ago
CytoSorbents to Report Q3 2018 Operating and Financial Results
MONMOUTH JUNCTION, N.J. , Oct. 31, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb ® blood purification technology to ...
- PR Newswire•4 months ago
CytoSorbents to Showcase CytoSorb® at Two Key European Medical Conferences
MONMOUTH JUNCTION, N.J. , Oct. 18, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly ...
- PR Newswire•5 months ago
CytoSorbents to Present at the Cantor Fitzgerald Global Healthcare Conference
MONMOUTH JUNCTION, N.J. , Oct. 3, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
- PR Newswire•5 months ago
CytoSorb® Assigned Dedicated Procedure Code in Switzerland
MONMOUTH JUNCTION, N.J. , Sept. 20, 2018 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO) a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation ...
